Metabolic dysfunction associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive inflammatory liver disease that represents the advanced, aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD).
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive inflammatory liver disease that represents the advanced, aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). It is histologically defined by hepatic steatosis (fat accumulation) occurring together with lobular inflammation, hepatocyte ballooning, and variable degrees of fibrosis. MASH marks a pivotal transition in the natural history of fatty liver disease: whereas simple steatosis is largely reversible, the sustained inflammatory and fibrogenic activity of MASH substantially raises the risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related death. The condition was formerly termed non-alcoholic steatohepatitis (NASH); the renaming to MASH is part of a broader reclassification of steatotic liver disease that emphasizes underlying metabolic dysfunction and removes the stigmatizing "non-alcoholic" and "fatty" terminology, while distinguishing it from alcohol-related and combined (MetALD) forms of liver injury.
MASH is tightly linked to the metabolic syndrome, and its development and progression are driven by obesity, type 2 diabetes, and insulin resistance, with lipotoxicity, oxidative stress, immune dysregulation, and activation of hepatic stellate cells contributing to inflammation and scarring. Its clinical burden extends beyond the liver: MASH is associated with substantial healthcare costs and with extra-hepatic complications, including cardiovascular disease and heart failure, and it commonly co-occurs with impaired kidney function as reflected in reduced glomerular filtration rate (eGFR). Because liver biopsy remains the diagnostic reference standard but is invasive, much current effort focuses on non-invasive risk stratification—using routine laboratory markers, imaging-derived measures such as liver MRI corrected T1 and proton density fat fraction, CT-based composite biomarkers, and machine-learning models—to identify patients with clinically significant fibrosis. Patients with stage F2–F3 (fibrotic) MASH constitute the principal target population for the emerging pharmacotherapies now entering clinical use.
Where the papers sit
16 papers from the last 6 months study metabolic dysfunction associated steatohepatitis directly · updated from PubMed 11 Nov 2026
Study type 0 clinical trials · 1 observational · 15 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Noninvasive MASH Diagnosis
Noninvasive biomarkers and imaging are moving MASH assessment beyond liver biopsy. MRI-PDFF, magnetic resonance elastography, cT1, and metabolomic panels recur as tools for detecting steatosis, fibrosis, and mortality risk. Screening increasingly targets children and adults with type 2 diabetes. Terminology, diagnostic thresholds, implementation, and healthcare costs remain active questions.
9 papers · 56.2%
-
MASH Fibrosis Mechanisms
Fibrosis regression is being pursued through macrophage biology, lipid metabolism, and metabolic intervention. Lipidated amino acid deficiency is linked to a PPARα/CCL2 pathway, while macrophage states emerge as context-dependent drivers. Bariatric surgery provides long-term paired-biopsy evidence for regression in compensated cirrhosis. Celastrol-based intestinal delivery represents an experimental therapeutic strategy, with translation beyond models still unresolved.
4 papers · 25%
-
MASH Drug Trials and Fibrosis
Resmetirom and simedeutirom trials are testing drug effects against fibrosis and cirrhosis progression. Week-52 outcomes and placebo-arm analyses anchor efficacy in histologic stage and clinical risk. Chinese data broaden simedeutirom evaluation beyond existing resmetirom evidence. Grade ≥3 treatment-emergent adverse events remain a recurring safety endpoint.
3 papers · 18.8%
Established fibrotic MASH, including cirrhosis, is potentially reversible rather than permanently fixed
The compensated MASH cirrhosis bariatric-surgery paired-biopsy study found histologic regression from stage 4 cirrhosis in 33% of patients after metabolic bariatric surgery, challenging the traditional assumption that MASH cirrhosis is irreversible 42969414Nov. Independently, the lipidated-amino-acid deficiency study in human and mouse MASH models showed that restoring hepatic N-oleoyl-leucine through PM20D1 overexpression or exogenous administration ameliorated both disease progression and established MASH-fibrosis 42784330Sep. Together, these findings shift the disease model from irreversible structural decline to established fibrotic disease that can, under distinct surgical and metabolic interventions, be therapeutically remodeled.
MASH is proposed as an integral component of a cardiovascular-renal-hepatic-metabolic syndrome
The cardiovascular-kidney-metabolic syndrome integration review assigns MASLD and MASH a structural role within an expanded cardiovascular-renal-hepatic-metabolic syndrome, rather than treating liver disease mainly as a hepatic complication of metabolic illness 42683763Sep. It links hepatic fibrosis and coexistent liver and kidney disease to additive, stage-dependent mortality risk and frames liver-directed and systemic therapies across a single multisystem construct. This introduces a new role for MASH as a defining component of a broader syndromic framework.
Papers
The 16 papers from the last 6 months that study metabolic dysfunction associated steatohepatitis directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Noninvasive MASH Diagnosis (9)
- MRI-based proton density fat fraction combined with adipose tissue for identifying metabolic dysfunction-associated steatohepatitis. Insights into imaging · 30 Oct 2026 PMID 42957938
- Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis. JHEP reports : innovation in hepatology · 7 Sept 2026 PMID 42705608
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
- Clinical and Metabolomic Panel for Noninvasive Screening of Biopsy-Confirmed MASH in Children and Adolescents. JHEP reports : innovation in hepatology · 30 Aug 2026 PMID 42669329
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany. Journal of comparative effectiveness research · 22 Jul 2026 PMID 42483986
- A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond. Nature communications · 20 Jul 2026 PMID 42477328
- Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation. Annals of hepatology · 18 Jun 2026 PMID 42315088
- Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk prediction. JHEP reports : innovation in hepatology · 17 Jun 2026 PMID 42309239
MASH Fibrosis Mechanisms (4)
- Cirrhosis Regression After Metabolic Bariatric Surgery in Patients With Compensated MASH Cirrhosis: A Long-term Paired Biopsy Study. Annals of surgery · 2 Nov 2026 PMID 42969414
- Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
- Context-Dependent Roles of Liver Macrophages in MASH. Seminars in liver disease · 15 Sept 2026 PMID 42743990
- Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis. Materials today. Bio · 13 Jul 2026 PMID 42440432
MASH Drug Trials and Fibrosis (3)
- Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The lancet. Gastroenterology & hepatology · 16 Oct 2026 PMID 42887516
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics · 29 Jul 2026 PMID 42527732
- Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials. Digestive diseases and sciences · 18 Jun 2026 PMID 42315723
By study type
Observational studies and case reports (1)
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
Unclassified: not yet indexed with MeSH (15)
- Cirrhosis Regression After Metabolic Bariatric Surgery in Patients With Compensated MASH Cirrhosis: A Long-term Paired Biopsy Study. Annals of surgery · 2 Nov 2026 PMID 42969414
- MRI-based proton density fat fraction combined with adipose tissue for identifying metabolic dysfunction-associated steatohepatitis. Insights into imaging · 30 Oct 2026 PMID 42957938
- Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The lancet. Gastroenterology & hepatology · 16 Oct 2026 PMID 42887516
- Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
- Context-Dependent Roles of Liver Macrophages in MASH. Seminars in liver disease · 15 Sept 2026 PMID 42743990
- Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis. JHEP reports : innovation in hepatology · 7 Sept 2026 PMID 42705608
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
- Clinical and Metabolomic Panel for Noninvasive Screening of Biopsy-Confirmed MASH in Children and Adolescents. JHEP reports : innovation in hepatology · 30 Aug 2026 PMID 42669329
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics · 29 Jul 2026 PMID 42527732
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany. Journal of comparative effectiveness research · 22 Jul 2026 PMID 42483986
- A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond. Nature communications · 20 Jul 2026 PMID 42477328
- Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis. Materials today. Bio · 13 Jul 2026 PMID 42440432
- Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials. Digestive diseases and sciences · 18 Jun 2026 PMID 42315723
- Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation. Annals of hepatology · 18 Jun 2026 PMID 42315088
- Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk prediction. JHEP reports : innovation in hepatology · 17 Jun 2026 PMID 42309239
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.